HOUSTON, TX--(Marketwire - December 19, 2011) - Power3 Medical Products, Inc. (OTCBB: PWRM), a biotechnology company, announced today the assembly of the foundational elements of its initiative to enter the adult stem cell arena, including:
1. A body of work on proof of concept, i.e. protein biomarkers: in human adult stem cells from patient's bone marrow and in stem cells and in media in culture;
2. The imminent conclusion of a sale of one of the company's diagnostic blood tests;
3. Preliminary agreement for co development with a company that manufactures stem cell culture equipment.
"This will provide significant scientific and economic foundation, and relationships to refocus our efforts on the very exciting and lucrative adult stem cell market," said Helen R. Park, Interim CEO.
Power3 Medical Products
Power3 Medical Products, Inc. a leading bio-technology company develops innovative diagnostic tests in neurodegenerative diseases (NuroPro®): Alzheimer's disease, Parkinson's disease and ALS (Lou Gehrig's disease) and cancer (BC-SeraPro™), discovers protein biomarkers and tests to detect disease, progression, drug response, and disease mechanisms, and to characterize adult stem cells.
For more information, please visit http://www.power3medical.com.
Safe Harbor Provision
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact, including, without limitation, statements regarding the company's future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements, subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2010 and its other filings and submissions with the Securities and Exchange Commission.